Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • About
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Refractory Lung Non-Small Cell Carcinoma”

229 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 229 results

Early research (Phase 1)Looking for participantsNCT02998567
What this trial is testing

Combination Study of Guadecitabine/ASTX727 and Pembrolizumab

Who this might be right for
Non Small Cell Lung Cancer
Royal Marsden NHS Foundation Trust 60
Testing effectiveness (Phase 2)Study completedNCT00064012
What this trial is testing

Bortezomib With or Without Docetaxel in Treating Patients With Relapsed or Refractory Advanced Non-Small Cell Lung Cancer

Who this might be right for
Lung Cancer
University of Wisconsin, Madison 4
Early research (Phase 1)Active Not RecruitingNCT05752552
What this trial is testing

Study to Determine the Safety and Pharmacokinetics of DO-2 in Patients With Advanced or Refractory Solid Tumours

Who this might be right for
Adult Solid TumorAdvanced Solid TumorRefractory Tumor+4 more
DeuterOncology 25
Testing effectiveness (Phase 2)Ended earlyNCT05551117
What this trial is testing

Vobramitamab Duocarmazine in Participants With Metastatic Castration Resistant Prostate Cancer and Other Solid Tumors

Who this might be right for
Castration-Resistant Prostatic CancerAndrogen-Independent Prostatic CancerAndrogen-Insensitive Prostatic Cancer+14 more
MacroGenics 192
Early research (Phase 1)Study completedNCT02835833
What this trial is testing

Study of Nintedanib Plus Bevacizumab in Advanced Solid Tumors

Who this might be right for
Renal Cell CarcinomaColorectal AdenocarcinomaNon-squamous Non-small Cell Lung Cancer+2 more
University of Alabama at Birmingham 21
Testing effectiveness (Phase 2)Study completedNCT00544960
What this trial is testing

Phase 2 Study of AT-101 in Combination With Docetaxel in Relapsed/Refractory Non-Small Cell Lung Cancer

Who this might be right for
Non-small Cell Lung Cancer
Ascenta Therapeutics 106
Testing effectiveness (Phase 2)UnknownNCT02005120
What this trial is testing

Intrapleural Administration of Bevacizumab Versus Endostar for Pleural Effusions in NSCLC

Who this might be right for
Non Small Cell Lung Cancer
Zhejiang University 20
Early research (Phase 1)WithdrawnNCT01820091
What this trial is testing

Phase 1 Study of Fusilev® to Prevent or Reduce Mucositis in Patients With Non-Small Cell Lung Cancer Receiving Folotyn®

Who this might be right for
Non-Small Cell Lung Cancer
Acrotech Biopharma Inc.
Early research (Phase 1)Ended earlyNCT07121829
What this trial is testing

Tovorafenib (DAY101) or in Combination With Pimasertib for Participants With Melanoma and Other Solid Tumors

Who this might be right for
MelanomaSolid TumorPilocytic Astrocytoma+7 more
Day One Biopharmaceuticals, Inc. 44
Testing effectiveness (Phase 2)Study completedNCT05253807
What this trial is testing

Study to Evaluate the Efficacy and Safety of Pemigatinib in Participants With Relapsed or Refractory Advanced Non-Small Cell Lung Cancer With an FGFR Alteration

Who this might be right for
Non-Small Cell Lung Cancer (NSCLC)
Incyte Corporation 8
Testing effectiveness (Phase 2)UnknownNCT02839954
What this trial is testing

CAR-pNK Cell Immunotherapy in MUC1 Positive Relapsed or Refractory Solid Tumor

Who this might be right for
Hepatocellular CarcinomaNon-small Cell Lung CancerPancreatic Carcinoma+4 more
PersonGen BioTherapeutics (Suzhou) Co., Ltd. 10
Testing effectiveness (Phase 2)Ended earlyNCT02706626
What this trial is testing

Trial of Brigatinib After Treatment With Next-Generation ALK Inhibitors

Who this might be right for
Non-Small Cell Lung Cancer
Criterium, Inc. 32
Testing effectiveness (Phase 2)Active Not RecruitingNCT04152499
What this trial is testing

Phase I-II, FIH, TROP2 ADC, Advanced Unresectable/Metastatic Solid Tumors, Refractory to Standard Therapies (KL264-01)

Who this might be right for
Epithelial Ovarian CancerGastric AdenocarcinomaGastroesophageal Junction Adenocarcinoma+7 more
Klus Pharma Inc. 1,410
Testing effectiveness (Phase 2)UnknownNCT00014547
What this trial is testing

BBR 3464 in Treating Patients With Metastatic Small Cell Lung Cancer That Has Not Responded to Previous Treatment

Who this might be right for
Lung Cancer
Theradex
Testing effectiveness (Phase 2)Ended earlyNCT00283634
What this trial is testing

Tarceva for Use in Patients With Relapsed or Refractory Metastatic Non-Small Cell Lung Cancer

Who this might be right for
NSCLC
Millennium Pharmaceuticals, Inc.
Early research (Phase 1)Study completedNCT00019019
What this trial is testing

Carboxyamidotriazole and Paclitaxel in Treating Patients With Advanced Solid Tumors or Refractory Lymphomas

Who this might be right for
Brain and Central Nervous System TumorsBreast CancerKidney Cancer+6 more
National Institutes of Health Clinical Center (CC) 70
Very early researchUnknownNCT04919616
What this trial is testing

An Exploratory Clinical Study of TILs in the Treatment of Recurrent / Refractory Non-small Cell Lung Cancer (NSCLC)

Who this might be right for
Carcinoma, Non-Small-Cell Lung
Shanghai OriginCell Therapeutics Co., Ltd. 15
Testing effectiveness (Phase 2)Ended earlyNCT00126451
What this trial is testing

A Clinical Trial of Oral Suberoylanilide Hydroxamic Acid (SAHA) in Patients With Relapsed or Refractory Breast, Colorectal and Non-Small Cell Lung Cancer (0683-011)(TERMINATED)

Who this might be right for
Breast CancerColorectal CancerNon-small-cell Lung Carcinoma
Merck Sharp & Dohme LLC 16
Testing effectiveness (Phase 2)Ended earlyNCT05275673
What this trial is testing

Sapanisertib in Relapsed/Refractory NFE2L2-Mutated and Wild-Type Squamous Non-Small Cell Lung Cancer

Who this might be right for
Non-Small Cell Lung CancerSquamous Non-small-cell Lung CancerSquamous Non-Small Cell Neoplasm of Lung+1 more
Faeth Therapeutics 7
Early research (Phase 1)Study completedNCT05159518
What this trial is testing

PRT2527 in Participants With Advanced Solid Tumors

Who this might be right for
SarcomaCastrate Resistant Prostate CancerHormone Receptor Positive HER2 Negative Breast Cancer+2 more
Prelude Therapeutics 30
Load More Results